Investor's Business Daily • 6 hours ago
Big U.S. pharmas AbbVie and Merck traded higher and flat, respectively, after reporting positive Q2 results, while France's Sanofi headed lower.
Forbes • 8 hours ago
Looking at the earnings posted by Merck & Co. (MRK), I could not help but compare and contrast them with what Sanofi (SNY) said this morning. Like Sanofi had with Lantus, Merck has a mega-blockbuster with Januvia. Just as Lantus was getting long in the tooth and facing patent expiration
Associated Press • 18 hours ago
On a per-share basis, the Paris-based company said it had profit of 51 cents. Earnings, adjusted for non-recurring costs, were 74 cents per share. The results met Wall Street expectations. The average ...
Associated Press • 19 hours ago
Drugmaker Sanofi has reported an 11 percent fall in profit in the second quarter despite double-digit growth of its biotech unit Genzyme. The Paris-based company reported Friday a fall in net income of ...
Bloomberg • 21 hours ago
Sanofi said it’s ready to act swiftly to reach a deal with U.S. biotechnology company Medivation Inc. as profit and sales declined, highlighting the need for new medicines to propel growth.
TheStreet.com • yesterday
Sanofi (SNY) stock is declining on Thursday afternoon ahead of the company’s 2016 second quarter results, due out before tomorrow’s market open.
After hours: 41.95-0.68 (-1.59%) as of 5:16 PM EDT
|Bid||42.00 x 200|
|Ask||43.58 x 200|
|52wk Range||37.41 - 54.98|
|Day's Range||41.62 - 42.74|
|Avg Vol (3m)||2,316,173|
As of 4:02 PM EDT. Market closed.